ClinicalTrials.gg

Program

benzgalantamine gluconate

Its studies are mostly in Alzheimer Disease, led by Alpha Cognition.

Furthest: phase 4, since May 19, 20261 company-led study, 1 open or runningNext primary completion: Apr 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alpha Cognition11 open or runningphase 4since May 19, 2026May 19, 2026Apr 2027phase 4 · NCT07633470

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 19, 2026First study: phase 4 study in Alzheimer DiseaseFirst studyNCT07633470 · 150 planned · United States

Ahead

  1. Apr 2027Primary completion: phase 4 study in Alzheimer DiseaseNCT07633470

TargetBeta

ACHE →read by rule
“Acetylcholinesterase inhibitor”ChEMBL 37, by rule

Other programs on ACHE

ProgramCompanyFurthest phaseStudies
DonepezilruleEisaiphase 483
huperzine Arulewanbangde-pharmaceutical-group-co-ltdphase 47
Z 338ruleZeria Pharmaceuticalphase 312

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07633470Alzheimer Disease · United States4RecruitingApr 2027150

How it is read

Names in the registry

  • “Zunveyl®”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.